November 25, 2024
Alkermes to Participate in Upcoming Investor Conferences
November 11, 2024
Alkermes to Participate in Two Upcoming Investor Conferences
November 07, 2024
Alkermes Highlights Presentations From Across Neuroscience Portfolio at Key Fall 2024 Scientific Conferences
Our most recent Corporate Responsibility Report, highlighting activities that took place in 2023, showcases Alkermes' commitment to acting as a responsible corporate citizen across a range of policies, programs and practices.
Our employees' dedication to patients and our communities is foundational to our culture. Hear how our team members contribute to building an organization dedicated to creating real impact.
We are honored to be recognized as an employer of choice in the life sciences industry. Visit our Awards & Recognition page to see the latest accolades bestowed on Alkermes, based on the results of a third-party survey shared with our U.S.-based employees.
Olanzapine and samidorphan
Schizophrenia and Bipolar I Disorder (Pediatric)
Phase 3
Olanzapine and samidorphan is a once-daily, oral atypical antipsychotic drug approved for adults in the U.S.
Olanzapine and samidorphan is currently being evaluated for pediatric use in a phase 3 study. For more information about this study, please visit enlightenyouthstudy.com (U.S. audiences only) or clinicaltrials.gov/study/NCT05303064.
ALKS 2680
Narcolepsy Type 1
Phase 2
Narcolepsy Type 2
Phase 2
Idiopathic Hypersomnia
Phase 1
ALKS 2680 is an investigational, oral orexin 2 receptor agonist in development as a once-daily treatment for narcolepsy type 1, narcolepsy type 2 and idiopathic hypersomnia.
ALKS 2680 is currently being evaluated in Vibrance-1, a phase 2 study in adults with narcolepsy type 1, and Vibrance-2, a phase 2 study in adults with narcolepsy type 2.
For more information about these studies, please visit vibrancestudies.com (for U.S. audiences only) or the respective clinicaltrials.gov listings:
Orexin Agonists
Neuroscience Indications
Preclinical
Neuroscience Indications
Preclinical
Additional orexin 2 receptor agonists are in preclinical research for the treatment of other neurological and psychiatric disorders.